X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Pfizer Inc. has agreed to plead guilty and pay $430 million in fines to settle charges that its Warner-Lambert unit flouted federal law by promoting non-approved uses for one of its drugs. The settlement with the world’s largest pharmaceutical company includes a $24.6 million payment for whistleblower David Franklin, who first reported the marketing abuses to authorities. Under the agreement released Wednesday by federal prosecutors, the company acknowledged spending hundreds of thousands of dollars to promote non-approved uses for the anti-seizure drug Neurontin, in part by paying doctors hefty speakers’ fees and flying them to lavish resorts as “educational” trips. “This illegal and fraudulent promotion scheme corrupted the information process relied upon by doctors in their medical decision-making, thereby putting patients at risk,” said U.S. Attorney Michael Sullivan, who joined senior Justice Department officials in Washington to announce the settlement Thursday. Pfizer agreed to plead guilty to violating the Food, Drug and Cosmetic Act and pay a $240 million criminal fine, the second-largest ever in a criminal health care fraud prosecution, according to the Justice Department. The company will also pay $152 million in civil fines to be shared among state and federal Medicaid agencies. Another $38 million would go to state consumer-protection agencies. “We believe we have exposed an illegal practice in the pharmaceutical industry that caused the Medicaid program to pay tens of millions of dollars for off-label prescriptions that were not eligible for reimbursement under the Medicaid program,” said Franklin’s attorney, Thomas Greene. A spokeswoman for the U.S. Attorney’s office in Boston, which helped negotiate the deal, declined to comment. The U.S. Department of Justice scheduled a news conference in Washington, D.C., to announce the settlement. The case began in 1996, when Franklin filed a whistleblower lawsuit against Parke-Davis and its parent company Warner-Lambert, alleging it used an illegal marketing plan to drive up sales of the anti-seizure drug Neurontin in the 1990s. Pfizer bought Warner-Lambert four years ago. The lawsuit alleged that while Neurontin was approved only as an epilepsy drug, the company promoted it for relieving pain, headaches, bipolar disorder and other psychiatric illnesses. While doctors can prescribe drugs for any use, the promotion of drugs for these so-called “off-label uses” is prohibited by the Food, Drug and Cosmetic Act. Last May, federal prosecutors in Boston filed a brief in support of Franklin’s lawsuit, and have since been in settlement negotiations with Pfizer to recover money the Medicaid program spent on Neurontin. Pfizer said the activity alleged in Franklin’s lawsuit and charged by prosecutors occurred years before it bought Warner-Lambert in 2000. “Pfizer is committed to compliance with all healthcare laws and FDA requirements and to high ethical standards in all aspects of its business practices,” the company said in a statement. The whistleblower lawsuit alleged that the company’s publicity plan for Neurontin included paying doctors to put their names on ghostwritten articles about Neurontin and to fly them to lavish resorts. One doctor received almost $308,000 to speak at conferences about the drug. Neurontin’s sales soared from $97.5 million in 1995 to nearly $2.7 billion in 2003. Shares of Pfizer fell 42 cents to $35.29 in afternoon trading on the New York Stock Exchange. Copyright 2004 Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 3 articles* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.